Biocartis Overview
- Year Founded
-
2007
- Status
-
Public
- Employees
-
420
- Stock Symbol
-
BCART
- Investments
-
4
- Share Price
-
$0.31
- (As of Friday Closing)
Biocartis General Information
Description
Biocartis Group NV is a commercial-stage molecular diagnostics company. It provides diagnostic solutions aimed at improving clinical practice for patients, clinicians, payers, and the industry. The firm has developed an MDx Idylla molecular diagnostic system for oncology and infectious disease segments. Its products include EGFR mutation assay, BRAF mutation test, NRAS mutation test, respiratory panel, etc. The firm derives the majority of its revenues from product sales.
Contact Information
Website
www.biocartis.comCorporate Office
- Generaal De Wittelaan 11B
- 2800 Mechelen
- Belgium
Corporate Office
- Generaal De Wittelaan 11B
- 2800 Mechelen
- Belgium
Biocartis Stock Performance
As of 22-Sep-2023, Biocartis’s stock price is $0.31. Its current market cap is $29M with 93.9M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.31 | $0.31 | $0.30 - $1.43 | $29M | 93.9M | 153K | -$1.14 |
Biocartis Financials Summary
As of 31-Dec-2023, Biocartis has a trailing 12-month revenue of $56M.
|
In Thousands, USD |
TTM 31-Dec-2023 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
|---|---|---|---|---|
| EV | 186,713 | 313,727 | ||
| Revenue | 55,971 | 55,971 | 60,436 | 57,068 |
| EBITDA | (37,764) | (37,764) | (46,212) | (63,403) |
| Net Income | (68,742) | (84,501) | ||
| Total Assets | 105,759 | 105,759 | 122,550 | 161,319 |
| Total Debt | 0 | 0 | 131,213 | 174,545 |
Biocartis Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Biocartis Comparisons
Industry
Financing
Details
Biocartis Competitors (34)
One of Biocartis’s 34 competitors is Novigenix, a Venture Capital-Backed company based in Epalinges, Switzerland.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Novigenix | Venture Capital-Backed | Epalinges, Switzerland | ||||
| Asuragen | Formerly VC-backed | Austin, TX | ||||
| Hain Lifescience | Corporate Backed or Acquired | Nehren, Germany | ||||
| Advanced Molecular Diagnostics | Corporation | Nottingham, United Kingdom | ||||
| Foundation Medicine | Formerly VC-backed | Cambridge, MA |
Biocartis Patents
Biocartis Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-3992302-A1 | Generic cartridge and method for multiplex nucleic acid detection | Pending | 29-Oct-2020 | ||
| AU-2021367997-A1 | Generic cartridge and method for multiplex nucleic acid detection | Pending | 29-Oct-2020 | ||
| CA-3200315-A1 | Generic cartridge and method for multiplex nucleic acid detection | Pending | 29-Oct-2020 | ||
| EP-4237584-A1 | Generic cartridge and method for multiplex nucleic acid detection | Pending | 29-Oct-2020 | ||
| US-20240035075-A1 | Generic cartridge and method for multiplex nucleic acid detection | Pending | 29-Oct-2020 | C12Q1/6851 |
Biocartis Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Biocartis Investments & Acquisitions (4)
Biocartis’s most recent deal was a Joint Venture with Molecular Diagnostics (Biocartis / Wondfo). The deal was made on 03-Sep-2018.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Molecular Diagnostics (Biocartis / Wondfo) | 03-Sep-2018 | Joint Venture | Diagnostic Equipment | ||
| Pronota | 04-Sep-2014 | Merger/Acquisition | Diagnostic Equipment | ||
| Royal Philips Electronics (Technology Platform) | 10-Feb-2010 | Merger/Acquisition | Diagnostic Equipment | ||
| Memobead Technologies | Merger/Acquisition | Discovery Tools (Healthcare) |
Biocartis ESG
Risk Overview
Risk Rating
Updated December, 17, 2024
30.77 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 15,104
Rank
Percentile
Healthcare
Industry
of 588
Rank
Percentile
Medical Devices
Subindustry
of 200
Rank
Percentile
Biocartis FAQs
-
When was Biocartis founded?
Biocartis was founded in 2007.
-
Where is Biocartis headquartered?
Biocartis is headquartered in Mechelen, Belgium.
-
What is the size of Biocartis?
Biocartis has 420 total employees.
-
What industry is Biocartis in?
Biocartis’s primary industry is Diagnostic Equipment.
-
Is Biocartis a private or public company?
Biocartis is a Public company.
-
What is Biocartis’s stock symbol?
The ticker symbol for Biocartis is BCART.
-
What is the current stock price of Biocartis?
As of 22-Sep-2023 the stock price of Biocartis is $0.31.
-
What is the current market cap of Biocartis?
The current market capitalization of Biocartis is $29M.
-
What is Biocartis’s current revenue?
The trailing twelve month revenue for Biocartis is $56M.
-
Who are Biocartis’s competitors?
Novigenix, Asuragen, Hain Lifescience, Advanced Molecular Diagnostics, and Foundation Medicine are some of the 34 competitors of Biocartis.
-
What is Biocartis’s annual earnings per share (EPS)?
Biocartis’s EPS for 12 months was -$1.14.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
